GU Cancers 2023 | The implications of CheckMate 650 for the clinical management of post-chemotherapy mCRPC

Russell Kent Pachynski, MD, Washington University School of Medicine, St. Louis, MO, talks on the clinical implications of the Phase II CheckMate 650 (NCT02985957) trial evaluating nivolumab plus ipilimumab, ipilimumab alone, or cabazitaxel in men with metastatic castration-resistant prostate cancer. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.